Journal
FUTURE MEDICINAL CHEMISTRY
Volume 7, Issue 6, Pages 727-735Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.15.26
Keywords
-
Categories
Funding
- Alnylam
- Eisai
- GlaxoSmithKline
- MSD
- Merck KGaA
- Novartis
- Pfizer
- Sanofi
Ask authors/readers for more resources
Schistosomiasis, one of 17 diseases deemed to be neglected by the World Health Organization, has received little attention from the biopharmaceutical industry. Due to this, only a handful of drugs have been developed to treat schistosomiasis, with only one, praziquantel, used in most endemic regions. Growing concern over resistance coupled with praziquantel's incomplete efficacy across all stages of the Schistosoma platyhelminth life cycle highlights the urgent need for new drugs. The WIPO Re: Search consortium is a platform whereupon biopharmaceutical company compounds are being repurposed to efficiently and cost-effectively develop new drugs for neglected diseases such as schistosomiasis. This article summarizes recent clinical-stage efforts to identify new antischistosomals and highlights biopharmaceutical company compounds with potential for repurposing to treat schistosomiasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available